Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GART | P22102 | 16/20 | 0.45 |
| ▸ | FOLR1 | P15328 | 11/20 | 0.45 |
| ▸ | SLC46A1 | Q96NT5 | 10/20 | 0.45 |
| ▸ | FOLR2 | P14207 | 9/20 | 0.45 |
| ▸ | SLC19A1 | P41440 | 5/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25904120 | 0.86 | GART (0.44) | GARTFOLR1SLC46A1FOLR2SLC19A1 | |
| SCHEMBL25899174 | 0.67 | DHFR (0.38) | XDH | |
| SCHEMBL23583491 | 0.66 | ESR1 (0.40) | — | |
| SCHEMBL24451674 | 0.66 | RAB9A (0.49) | — | |
| SCHEMBL22725670 | 0.65 | RAB9A (0.51) | — | |
| SCHEMBL8259759 | 0.65 | NFKB1 (0.51) | — | |
| SCHEMBL21921107 | 0.63 | ESR1 (0.37) | — | |
| SCHEMBL18552695 | 0.62 | GART (0.69) | GARTFOLR1SLC46A1FOLR2SLC19A1 | |
| SCHEMBL24629146 | 0.62 | CYP3A4 (0.42) | XDHPARP1 | |
| SCHEMBL22526065 | 0.62 | NFKB1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, FCGR3B, FCGR2A | GART 1094/4885FOLR1 297/4885SLC46A1 1864/4885 |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, ASGR1, FCGR3B | GART 1597/4885FOLR1 451/4885SLC46A1 2039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.